Journal
ONCOIMMUNOLOGY
Volume 10, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2020.1865670
Keywords
STK11; KEAP1; NSCLC; immune checkpoint inhibitor
Categories
Funding
- Shanghai Municipal Human Resource and Social Security Bureau Talent Project [052]
- National Natural Science Foundation of China [81601988, 81602078, 81502450, 81472642, 81802370]
- Science and Technology Commission of Shanghai Municipality, China [18441904700]
- Shanghai Sailing Program [18YF1404200]
- Shanghai Chest Hospital Project of Collaborative Innovation [YJXT20190102]
Ask authors/readers for more resources
Somatic mutations of STK11 or KEAP1 in aNSCLC patients are associated with poor clinical outcomes when receiving different treatments. This study compared the efficacy of atezolizumab versus docetaxel in SKmut aNSCLC patients, showing that atezolizumab was associated with significantly longer overall survival compared to docetaxel. Furthermore, patients with FAT3 mutation or high TMB and PD-L1 expression may predict favorable response to atezolizumab treatment.
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work better for STK11 or KEAP1 mutated (SKmut) aNSCLC patients is unknown. In this study, the efficacy of atezolizumab versus docetaxel in SKmut aNSCLC was compared. A total of 157 SKmut aNSCLC patients were identified from POPLAR and OAK trials, who were tested by blood-based FoundationOne next-generation sequencing assay. Detailed clinical data and genetic alterations were collected. Two independent cohorts were used for biomarker validation (n = 30 and 20, respectively). Median overall survival was 7.3 months (95% confidence interval [CI], 4.8 to 9.9) in the atezolizumab group versus 5.8 months (95% CI, 4.4 to 7.2) in the docetaxel group (adjusted hazard ratio [HR] for death, 0.70; 95% CI, 0.49 to 0.99; P = .042). Among atezolizumab-treated patients, objective response rate, disease control rate, and durable clinical benefit were higher when blood tumor mutation burden (bTMB) and PD-L1 being higher (biomarker 1, n = 61) or with FAT3 mutation-positive tumors (biomarker 2, n = 83) than otherwise. The interactions for survival between these two biomarkers and treatments were significant, which were further validated in two independent cohorts. In SKmut patients with aNSCLC, atezolizumab was associated with significantly longer overall survival in comparison to docetaxel. Having FAT3 mutation or high TMB and PD-L1 expression potentially predict favorable response in SKmut patients receiving atezolizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available